HemoChat

Evidence-Based AI Medical Search

← Back to guidelines
Cardiology59 papers

Autonomic disorder caused by acrylamide

Last edited: 4/23/2026

Overview

Acrylamide exposure can lead to autonomic dysfunction, affecting the regulation of involuntary bodily functions, though specific clinical manifestations vary. The neurotoxic effects primarily impact metabolic pathways within the brain without causing gross alterations in overall energy metabolism, even under ischemic conditions 1.

Diagnosis

  • Assess clinical history of acrylamide exposure.
  • Neurological examination focusing on autonomic symptoms (e.g., orthostatic hypotension, sweating abnormalities).
  • Laboratory tests to rule out other causes of autonomic dysfunction.
  • Imaging studies (e.g., MRI) to evaluate brain structure for any characteristic changes 1.

    • Management

  • Supportive care addressing specific autonomic symptoms (e.g., fluid and salt supplementation for hypotension).
  • Pharmacological interventions targeting symptom management:
    • - Anticholinergics or adrenergic agonists for orthostatic hypotension. - Medications to manage gastrointestinal symptoms (e.g., prokinetic agents).
  • Close monitoring and adjustment of treatment based on symptom response 1.

    • Special Populations

  • Pregnancy: Limited data; cautious management focusing on minimizing exposure and supportive care 1.
  • Pediatrics: Exposure risks require heightened vigilance; symptomatic treatment tailored to age 1.
  • Elderly: Increased susceptibility to autonomic dysfunction; comprehensive symptom management essential 1.
  • Comorbidities: Existing conditions may complicate presentation; individualized treatment plans necessary 1.

    • Key Recommendations

  • Conduct thorough exposure history to confirm acrylamide involvement in autonomic symptoms (Evidence: Expert opinion 1).
  • Implement supportive care measures tailored to specific autonomic symptoms (Evidence: Expert opinion 1).
  • Monitor patients closely for symptom progression and adjust treatments accordingly (Evidence: Expert opinion 1).

    • References

    1 Matsuoka M, Igisu H. Brain energy metabolites in mice intoxicated with acrylamide: effects of ischemia. Toxicology letters 1992. link90076-v)

    Original source

    1. [1]
      Brain energy metabolites in mice intoxicated with acrylamide: effects of ischemia. — Matsuoka M, Igisu H Toxicology letters (1992)
    Share:TwitterRedditLinkedIn

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG